Literature DB >> 9293786

Specificity of radioiodinated MIBG for neural crest tumors in childhood.

A Leung1, B Shapiro, R Hattner, E Kim, J de Kraker, N Ghazzar, O Hartmann, C A Hoefnagel, D A Jamadar, R Kloos, P Lizotte, J Lumbroso, V Rufini, B L Shulkin, J C Sisson, A Thein, L Troncone.   

Abstract

UNLABELLED: The high sensitivity of metaiodobenzylguanidine (MIBG) scintigraphy for sympathomedullary tumors such as neuroblastoma and pheochromocytoma is well documented. The specificity of MIBG scintigraphy for these tumors is also high but has been incompletely characterized for other neural crest tumors and non-neural crest tumors of childhood.
METHODS: The medical records and MIBG scans of all children who had undergone MIBG scintigraphy for known or suspected neuroblastoma or pheochromocytoma were retrospectively reviewed at five major referral centers. Those patients found to have pathologies other than neuroblastoma or pheochromocytoma form the basis of this study.
RESULTS: One hundred children with a total of 110 lesions met the inclusion criteria. All had negative MIBG scans except 1 of 2 children with infantile myofibromatosis, 1 of 2 with neuroendocrine carcinomas, 1 of 2 with pancreaticoblastomas and 1 of 10 with primitive neuroectodermal tumors.
CONCLUSION: MIBG scintigraphy is highly specific for neuroblastoma and pheochromocytoma. Only 4% (4/100) of nonsympathomedullary tumors (non-pheochromocytoma and non-neuroblastoma) in childhood showed MIBG uptake, of which only 2% (2/100) were of non-neural crest origin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9293786

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

1.  Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.

Authors:  Alexander Kroiss; Daniel Putzer; Christian Uprimny; Clemens Decristoforo; Michael Gabriel; Wolfram Santner; Christof Kranewitter; Boris Warwitz; Dietmar Waitz; Dorota Kendler; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

2.  Guidelines for radioiodinated MIBG scintigraphy in children.

Authors:  Pierre Olivier; Paula Colarinha; Jure Fettich; Sibylle Fischer; Jörgen Frökier; Francesco Giammarile; Isky Gordon; Klaus Hahn; Levent Kabasakal; Mike Mann; Mercedes Mitjavila; Amy Piepsz; Ute Porn; Rune Sixt; Jeannette van Velzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-26       Impact factor: 9.236

3.  131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

4.  131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Francesco Giammarile; Cumali Aktolun; Richard P Baum; Angelika Bischof Delaloye; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Giovanna Pepe; Sven N Reske; Maria R Castellani; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

5.  Guidelines on nuclear medicine imaging in neuroblastoma.

Authors:  Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10       Impact factor: 9.236

Review 6.  Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Authors:  Egesta Lopci; Arturo Chiti; Maria Rita Castellani; Giovanna Pepe; Lidija Antunovic; Stefano Fanti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

7.  High uptake of 123I-metaiodobenzylguanidine related to olfactory neuroblastoma revealed by single-photon emission CT.

Authors:  T Sasajima; H Kinouchi; N Tomura; J Watarai; K Mizoi
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

Review 8.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

Review 9.  Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

Authors:  K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

Review 10.  123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Authors:  Gitta Bleeker; Godelieve A M Tytgat; Judit A Adam; Huib N Caron; Leontien C M Kremer; Lotty Hooft; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.